Neuren Pharmaceuticals Ltd  

(Public, ASX:NEU)   Watch this stock  
Find more results for NEU
-0.010 (-5.88%)
Jan 28 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.16 - 0.17
52 week 0.06 - 0.19
Open 0.17
Vol / Avg. 3.20M/4.06M
Mkt cap 255.24M
P/E     -
Div/yield     -
EPS -0.01
Shares 1.59B
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -270.31% -209.96%
Operating margin -241.55% -182.84%
EBITD margin - -120.99%
Return on average assets -37.17% -59.91%
Return on average equity -40.35% -67.13%
CDP Score - -


Suite 201 697 Burke Road, Camberwell
+61-3-90920480 (Phone)

Website links


Neuren Pharmaceuticals Limited is a New Zealand-based company. The Company is a biopharmaceutical company focusing on the development of drugs for neurological disorders and cancer. In neurology, the drugs target both acute indications, such as traumatic brain injury and concussion, as well as chronic conditions, such as autism spectrum disorders and neurodegenerative diseases. In oncology, the focus is on developing monoclonal antibodies to treat breast and other cancers. The Company has three lead candidates, which include NNZ-2566 and Motiva in clinical development to treat a range of acute and chronic neurological conditions, and NNZ-2591 in preclinical development for chronic neurodegenerative conditions. The Company has operations in New Zealand and the United States.

Officers and directors

Richard Treagus Executive Chairman of the Board
Jon Pilcher Chief Financial Officer, Company Secretary
James Shaw Chief Operating Officer
Larry Glass Chief Science Officer, Executive Director
Joseph Horrigan Vice President - Clinical Development and Medical Affairs
Robert Waring Company Secretary
Bruce Alan Hancox Independent Non-Executive Director
Trevor D. Scott Independent Non-Executive Director